Trial · NCT02974114
Outcomes12
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change From Pain Free State (Day 3) in Error Adjusted Simple Reaction Time (SRT) in the Pain State (Day 2) | At Day 2 (pre and post-treatment) and Day 3 of the study | Modified Intent-to-Treat (mITT, N=20) Population: All the participants who were randomized, received at least one dose of the study treatment and had at least one post-baseline assessment without any violation of study inclusion-exclusion criteria were included in the mITT population. | milliseconds (msec) | MEDIAN |
| PRIMARY | Change From Pain-free State (Day 3) in Reaction Time in the Pain State (Day 2) | At Day 2 (pre and post-treatment) and Day 3 of the study | Modified Intent-to-Treat (mITT, N=20) Population: All the participants who were randomized, received at least one dose of the study treatment and had at least one post-baseline assessment without any violation of study inclusion-exclusion criteria were included in the mITT population. | msec | MEDIAN |
| PRIMARY | Change From Pain-free State (Day 3) in Number of One Touch Stockings (OTS) of Cambridge Assessment Problems (on Which the First Box Choice Made Was Correct) in the Pain State (Day 2) | At Day 2 (pre and post treatment) and Day 3 of the study | Modified Intent-to-Treat (mITT, N=20) Population: All the participants who were randomized, received at least one dose of the study treatment and had at least one post-baseline assessment without any violation of study inclusion-exclusion criteria were included in the mITT population. | OTS of correct first box choice | MEAN |
| PRIMARY | Change From Pain-free State (Day 3) in Attention Switching Task (AST) Congruency Cost in the Pain State (Day 2) | At Day 2 (pre and post treatment) and Day 3 of the study | Modified Intent-to-Treat (mITT, N=20) Population: All the participants who were randomized, received at least one dose of the study treatment and had at least one post-baseline assessment without any violation of study inclusion-exclusion criteria were included in the mITT population. | msec | MEDIAN |
| PRIMARY | Change From Pain-free State (Day 3) in Spatial Working Memory (SWM) Between Errors in the Pain State (Day 2) | At Day 2 (pre and post treatment) and Day 3 of the study | Modified Intent-to-Treat (mITT, N=20) Population: All the participants who were randomized, received at least one dose of the study treatment and had at least one post-baseline assessment without any violation of study inclusion-exclusion criteria were included in the mITT population. | SWM between errors | MEAN |
| PRIMARY | Change From Pain-free State (Day 3) in Rapid Visual Information Processing A Prime (RVPA) in the Pain State (Day 2) | At Day 2 (pre and post treatment) and Day 3 of the study | Modified Intent-to-Treat (mITT, N=20) Population: All the participants who were randomized, received at least one dose of the study treatment and had at least one post-baseline assessment without any violation of study inclusion-exclusion criteria were included in the mITT population. | msec | MEDIAN |
| SECONDARY | Change From Pain-free State (Day 3) in Grip Force in Pain State (Day 2) | At Day 2 (pre and post-treatment) and Day 3 of the study | Modified Intent-to-Treat (mITT, N=20) Population: All the participants who were randomized, received at least one dose of the study treatment and had at least one post-baseline assessment without any violation of study inclusion-exclusion criteria were included in the mITT population. | Kilogram (Kg) | MEAN |
| SECONDARY | Change From Pain-free State (Day 3) in Time to Standing in Pain State (Day 2) | At Day 2 (pre and post treatment) and Day 3 of the study | Modified Intent-to-Treat (mITT, N=20) Population: All the participants who were randomized, received at least one dose of the study treatment and had at least one post-baseline assessment without any violation of study inclusion-exclusion criteria were included in the mITT population. | Seconds | MEDIAN |
| SECONDARY | Change From Pain-free State (Day 3) in Ground Reaction Force (GRF) in Pain State (Day 2) | At Day 2 (pre and post treatment) and Day 3 of the study | Modified Intent-to-Treat (mITT, N=20) Population: All the participants who were randomized, received at least one dose of the study treatment and had at least one post-baseline assessment without any violation of study inclusion-exclusion criteria were included in the mITT population. | Newtons | MEAN |
| SECONDARY | Change From Pain-free State (Day 3) in Contact Phase in Pain State (Day 2) | At Day 2 (pre and post treatment) and Day 3 of the study | Modified Intent-to-Treat (mITT, N=20) Population: All the participants who were randomized, received at least one dose of the study treatment and had at least one post-baseline assessment without any violation of study inclusion-exclusion criteria were included in the mITT population. | Seconds | MEDIAN |
| SECONDARY | Change From Pain-free State (Day 3) in Stride Length in Pain State (Day 2) | At Day 2 (pre and post treatment) and Day 3 of the study | Modified Intent-to-Treat (mITT, N=20) Population: All the participants who were randomized, received at least one dose of the study treatment and had at least one post-baseline assessment without any violation of study inclusion-exclusion criteria were included in the mITT population. | Centimeter | MEAN |
| SECONDARY | Change From Pain-free State (Day 3) in Walking Speed in Pain State (Day 2) | At Day 2 (pre and post-treatment) and Day 3 | Modified Intent-to-Treat (mITT, N=20) Population: All the participants who were randomized, received at least one dose of the study treatment and had at least one post-baseline assessment without any violation of study inclusion-exclusion criteria were included in the mITT population. | meters/second | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02974114/outcomes